The use of sclerostin antibodies in the treatment of osteoporosis has raised concerns regarding cardiovascular side‐effects.(87, 88, 89) In a phase II trial of sotatercept (activin receptor type IIA fusion protein trap) effect on hemoglobin in dialysis patients, a positive effect on aorta calcification and BMD was reported.(84). The gene discussed is ACVR2A; the disease is osteoporosis.